Literature DB >> 15385814

Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction.

Junchao Cai1, Paul I Terasaki, Debra D Bloom, Jose R Torrealba, Andreas Friedl, Hans W Sollinger, Stuart J Knechtle.   

Abstract

BACKGROUND: In this study, we determined whether Campath-1H induction followed by sirolimus monotherapy inhibited alloantibody production in renal transplantation. Second, we evaluated the correlation between human leukocyte antigen (HLA) antibody production and serum creatinine levels.
METHODS: Sera were taken 1 to 24 months after transplantation from 24 patients treated with Campath-1H and sirolimus and tested for serum creatinine and HLA-specific antibody by using flow cytometry and enzyme-linked immunosorbent assay.
RESULTS: Ten (42%) of the 24 patients treated with Campath-1H and sirolimus produced HLA antibodies. Six of these 10 developed both donor-specific antibodies (DSAs) and non-donor-specific antibodies (NDSAs), whereas only NDSAs were detected in the other four patients. In patients with biopsy-diagnosed humoral rejection (C4d+), serum levels of both DSA and NDSA significantly correlated with patient serum creatinine levels. Rejection treatment successfully reduced both DSAs and NDSAs and reversed humoral rejection.
CONCLUSIONS: The numeric relationship between serum creatinine and DSA levels suggests a causal relationship between alloantibody and transplant rejection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385814     DOI: 10.1097/01.tp.0000134398.86243.81

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  13 in total

1.  Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques.

Authors:  E K Page; A J Page; J Kwun; A C Gibby; F Leopardi; J B Jenkins; E A Strobert; M Song; R A Hennigar; N Iwakoshi; S J Knechtle
Journal:  Am J Transplant       Date:  2012-07-09       Impact factor: 8.086

2.  The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss.

Authors:  C A Schinstock; F Cosio; W Cheungpasitporn; D M Dadhania; M J Everly; M D Samaniego-Picota; L Cornell; M D Stegall
Journal:  Am J Transplant       Date:  2017-01-25       Impact factor: 8.086

Review 3.  Development of tolerogenic strategies in the clinic.

Authors:  Stuart J Knechtle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

4.  Alemtuzumab as compared to alternative contemporary induction regimens.

Authors:  John C LaMattina; Joshua D Mezrich; R Michael Hofmann; David P Foley; Anthony M D'Alessandro; Hans W Sollinger; John D Pirsch
Journal:  Transpl Int       Date:  2012-03-06       Impact factor: 3.782

Review 5.  Crosstalk Between T and B Cells in the Germinal Center After Transplantation.

Authors:  Jean Kwun; Miriam Manook; Eugenia Page; Christopher Burghuber; Jungjoo Hong; Stuart J Knechtle
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

6.  Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment.

Authors:  J Kwun; B C Oh; A C Gibby; R Ruhil; V T Lu; D W Kim; E K Page; O P Bulut; M Q Song; A B Farris; A D Kirk; S J Knechtle; N N Iwakoshi
Journal:  Am J Transplant       Date:  2012-07-03       Impact factor: 8.086

7.  Renal transplantation in children managed with lymphocyte depleting agents and low-dose maintenance tacrolimus monotherapy.

Authors:  Demetrius Ellis; Ron Shapiro; Michael Moritz; Abhay Vats; Amit Basu; Henkie Tan; Liise Kayler; Janine Janosky; Thomas E Starzl
Journal:  Transplantation       Date:  2007-06-27       Impact factor: 4.939

8.  Tolerogenicity of donor major histocompatibility complex-matched skin grafts in previously tolerant Massachusetts general hospital miniature swine.

Authors:  Joshua Weiner; Joseph Scalea; Yoshinori Ishikawa; Masayoshi Okumi; Adam Griesemer; Atsushi Hirakata; Justin Etter; Bradford Gillon; Shannon Moran; Akira Shimizu; Kazuhiko Yamada; David H Sachs
Journal:  Transplantation       Date:  2012-12-27       Impact factor: 4.939

9.  BAFF is increased in renal transplant patients following treatment with alemtuzumab.

Authors:  D Bloom; Z Chang; K Pauly; J Kwun; J Fechner; C Hayes; M Samaniego; S Knechtle
Journal:  Am J Transplant       Date:  2009-06-12       Impact factor: 8.086

10.  B-cell tolerance in transplantation: is repertoire remodeling the answer?

Authors:  Ronald F Parsons; Kumar Vivek; Robert R Redfield; Thi-Sau Migone; Michael P Cancro; Ali Naji; Hooman Noorchashm
Journal:  Expert Rev Clin Immunol       Date:  2009-11       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.